2021 年第三季度报告 单位：元 币种：人民币 证券代码：600789 证券简称：鲁抗医药 山东鲁抗医药股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|------------------|------------------------------|------------------|----------------------- ...

2021 年半年度报告 公司代码：600789 公司简称：鲁抗医药 山东鲁抗医药股份有限公司 2021 年半年度报告 1 / 144 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人彭欣、主管会计工作负责人李利及会计机构负责人（会计主管人员）荣姝伟声明： 保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性描述，不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风 ...

Financial Performance - The company's operating revenue for 2020 was RMB 4,205,109,097.87, representing a 12.66% increase compared to RMB 3,732,718,882.94 in 2019[26]. - The net profit attributable to shareholders of the listed company was RMB 227,876,516.65, an increase of 87.94% from RMB 121,251,309.89 in 2019[26]. - The basic earnings per share increased to CNY 0.26, representing an 85.71% increase from CNY 0.14 in the previous year[28]. - The diluted earnings per share also rose to CNY 0.25, an increase of 78.57% compared to CNY 0.14 in the previous year[28]. - The weighted average return on net assets was 7.31%, an increase of 3.23 percentage points from 4.08% in the previous year[28]. - The total assets at the end of the reporting period were CNY 7,272,824,836.06, a 2.59% increase from CNY 7,089,268,238.84 at the end of the previous year[28]. - The net assets attributable to shareholders increased by 6.38% to CNY 3,213,975,896.55 from CNY 3,021,159,128.79 in the previous year[28]. - The company reported a total revenue of CNY 1,139,500,133.00 in the fourth quarter, showing a sequential increase from CNY 1,066,634,009.00 in the third quarter[29]. - The net cash flow from operating activities was CNY 234,552,377.73, down 35.18% from CNY 361,866,734.40 in the previous year[28]. - The company achieved an annual revenue of CNY 4.205 billion, representing a year-on-year growth of 12.66%[62]. - The net profit attributable to shareholders reached CNY 228 million, with a significant year-on-year increase of 87.94%[62]. Dividends and Profit Distribution - The board proposed a cash dividend of RMB 0.55 per 10 shares, totaling RMB 48,412,635.43 to be distributed to shareholders[7]. - The net profit attributable to ordinary shareholders for the fiscal year 2020 was 227,876,516.65 RMB, representing a profit distribution ratio of 21.25%[173]. - The company implemented a cash dividend plan for the fiscal year 2020, distributing a cash dividend of 0.55 RMB per 10 shares, totaling 48,412,635.43 RMB (including tax) to shareholders[173]. Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[11]. - The company has outlined various risks and corresponding countermeasures in its operational analysis section[11]. - The company faced risks related to raw material procurement due to factors such as increased environmental investment and rising labor costs, which could lead to a surge in procurement costs or shortages[167]. - The company has established a comprehensive quality assurance system in compliance with national GMP certification, ensuring controlled production processes to mitigate product quality risks[166]. - The company has a dynamic management system for suppliers and implements annual supply agreements to ensure supply security and control procurement costs[167]. - The company faces risks related to industry policy changes, R&D challenges, and environmental regulations, which could impact future operations[160][161][162]. Research and Development - The company’s R&D expenses increased by 36.77% to CNY 192.63 million, reflecting a commitment to innovation[63]. - The total R&D investment reached ¥241,683,364.30, representing 5.75% of operating income, exceeding the industry average[80]. - The company is focusing on increasing R&D investment, with development expenditures rising to ¥179,052,332.02, accounting for 2.46% of total assets, up 21.93% from the previous period[87]. - The company is actively expanding its product pipeline with a focus on both innovative and generic drugs[124]. - The company is committed to maintaining a competitive R&D investment level compared to industry peers, with a higher R&D investment ratio than some competitors[129]. - Major R&D projects included the registration of Acarbose tablets with an investment of 8.79 million RMB, and the consistency evaluation of Entecavir dispersible tablets with an investment of 5.46 million RMB, showing significant year-on-year changes of 162.76% and 117.22% respectively[131]. Market and Sales Performance - The sales of non-antibiotic products increased by more than 10% year-on-year[50]. - The sales volume of major veterinary drug formulations grew by over 50% year-on-year due to active adjustments in marketing strategies[50]. - Domestic revenue accounted for CNY 3.419 billion, with a year-on-year increase of 17.89%[68]. - The company’s products ranked among the top ten in the national market for 57 specifications, and it was ranked 46th in the "Top 100 Comprehensive Strength of China's Chemical Pharmaceutical Industry" in 2020[49]. - The company is focusing on expanding its market share in both domestic and international markets through innovative marketing strategies and product differentiation[50]. Operational Efficiency - Cost reduction efforts led to a total cost decrease of approximately CNY 113 million, with a comparable cost reduction rate exceeding 4%[58]. - The asset-liability ratio decreased to 53.81%, down by 1.45 percentage points year-on-year[57]. - The company implemented automation and intelligent construction, reducing personnel by over 20%[58]. - The company is focusing on reducing operational costs through information technology upgrades and standardizing data processes[154]. Compliance and Governance - The company has committed to ensuring the accuracy and completeness of its financial reports, as stated by its management[6]. - The audit report issued by the accounting firm was a standard unqualified opinion[6]. - The company has not faced any violations in decision-making procedures regarding external guarantees[9]. - The company reported no major litigation or arbitration matters during the fiscal year[179]. - The company has not disclosed any significant related party transactions for the fiscal year[181]. - The company has not faced any risks of suspension or termination of listing during the reporting period[177]. Strategic Initiatives - The company plans to adapt its operational strategies and product structure in response to national pharmaceutical policies, aiming to maintain and enhance market share in specific segments[102]. - The company intends to shift its product structure from a single focus on antibiotics to a dual focus on antibiotics and innovative drugs[106]. - The company aims to improve product quality and cost-effectiveness while expanding new sales channels and enhancing logistics services[102]. - The company plans to accelerate the industrialization of new products and aims to double the revenue from calcium acetate granules[153]. - The company intends to complete multiple international product registrations within the year to enhance product quality assurance and international competitiveness[153].

2021 年第一季度报告 公司代码：600789 公司简称：鲁抗医药 山东鲁抗医药股份有限公司 2021 年第一季度报告 1 / 18 2021 年第一季度报告 一、 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 18 2021 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 未出席董事情况 | --- | --- | --- | --- | |----------------|----------------|----------------------------|--------------| | 未出席董事姓名 | 未出席董事职务 | 未出席原因的说明 | 被委托人姓名 | | 颜骏廷 | 董事 | 因公出差，未能亲自参加会议 | 彭 欣 | | 黄正明 | 独立董事 | 因公出差，未能亲自参加会议 | 孙宗彬 | ...

2020 年第三季度报告 公司代码：600789 公司简称：鲁抗医药 山东鲁抗医药股份有限公司 2020 年第三季度报告 1 / 28 2020 年第三季度报告 一、 重要提示 二、 公司基本情况. 11[ 重要事项 四、 附录 目录 2 / 28 2020 年第三季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人彭欣、主管会计工作负责人李利及会计机构负责人（会计主管人员）荣姝伟保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |------------------------------------------------|------------------------------|------------------------------------|-- ...

2020 年第三季度报告 公司代码：600789 公司简称：鲁抗医药 山东鲁抗医药股份有限公司 2020 年第三季度报告正文 1 / 6 2020 年第三季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人彭欣、主管会计工作负责人李利及会计机构负责人（会计主管人员）荣姝伟保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司主要财务数据和股东变化 2.1 主要财务数据 | --- | --- | --- | --- | |-----------------------------------------------|------------------------------|------------------------------------|-------------------------------| | | 本报告期末 | 上年度末 | ...

证券代码：600789 证券简称：鲁抗医药 公告编号：2020—041 山东鲁抗医药股份有限公司 关于参加山东辖区上市公司2020年度投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与广大投资者的沟通交流，做好投资者关系管理工作，山东鲁 抗医药股份有限公司（以下简称"公司"） 将参加由山东证监局、山东上市公司 协会与深圳市全景网络有限公司联合举办的"山东辖区上市公司 2020 年度投资 者网上集体接待日"活动，现将有关事项公告如下： 本次集体接待日活动将采取网络远程的方式举行，投资者可以登录"全景 • 路演天下"网站（http://rs.p5w.net）参与本次活动。活动时间为 2020 年 9 月 29 日（星期二）15:00 至 16:55。 届时公司财务总监李利先生、董事会秘书田立新先生、证券事务代表包强明 先生将通过网络在线交流形式与投资者就公司治理、经营状况等投资者关注的问 题进行沟通，欢迎广大投资者积极参与。 特此公告。 山东鲁抗医药股份有限公司董事会 二〇二〇年 ...

公司代码：600789 公司简称：鲁抗医药 2020 年半年度报告 山东鲁抗医药股份有限公司 2020 年半年度报告 1 / 150 2020 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人彭欣、主管会计工作负责人李利及会计机构负责人（会计主管人员）荣姝伟声明： 保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性描述，不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在本报告中详细 阐述公司在生产经营过程中可能面临的各种风险及应对措施，敬请查阅 ...

2020 年第一季度报告 公司代码：600789 公司简称：鲁抗医药 山东鲁抗医药股份有限公司 2020 年第一季度报告 1 / 24 2020 年第一季度报告 一、 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 24 2020 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人彭欣、主管会计工作负责人李利及会计机构负责人（会计主管人员）荣姝伟保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-------------------------------------------------|--------------- ...

Financial Performance - The company's operating revenue for 2019 was approximately CNY 3.73 billion, representing a year-on-year increase of 12.11% compared to CNY 3.33 billion in 2018[25]. - Net profit attributable to shareholders decreased by 24.87% to CNY 121.25 million from CNY 161.39 million in the previous year[25]. - The net profit after deducting non-recurring gains and losses was CNY 63.32 million, down 40.20% from CNY 105.89 million in 2018[25]. - The cash flow from operating activities was CNY 361.87 million, showing a slight increase of 3.07% from CNY 351.09 million in the previous year[25]. - The total assets of the company increased by 7.95% to CNY 7.09 billion from CNY 6.57 billion at the end of 2018[25]. - Basic earnings per share decreased by 26.32% to CNY 0.14 from CNY 0.19 in 2018[25]. - The weighted average return on equity decreased by 1.96 percentage points to 4.08% from 6.04% in the previous year[25]. - The company achieved an annual revenue of 3.733 billion RMB, representing a year-on-year growth of 12.11%[64]. - The net profit attributable to shareholders decreased to 121 million RMB, a decline of 24.87% compared to the previous year[64]. - The operating cash flow net amount increased to 362 million RMB, showing a slight increase of 0.11 million RMB year-on-year[64]. Dividend and Profit Distribution - The board proposed a cash dividend of CNY 0.45 per 10 shares, totaling CNY 39,610,338.08 for 2019, based on a total share capital of 880,229,735 shares[7]. - The company reported a retained profit of RMB 33,278,592.21 to be carried forward to the next fiscal year[183]. - The net profit attributable to ordinary shareholders for 2019 was RMB 121,251,309.89, with a dividend payout ratio of 32.67%[184]. - The company maintained a profit distribution policy that protects the rights of minority investors, with independent directors fulfilling their responsibilities[183]. - The total share capital after the 2019 distribution will be 880,229,735 shares, following the proposed capital increase[183]. - The company has not made any adjustments to its profit distribution policy during the reporting period[184]. Risk Management - There were no significant risks impacting the company's operations during the reporting period[9]. - The company has a comprehensive risk management strategy in place to address potential operational risks[9]. - The company emphasizes that forward-looking statements do not constitute a commitment to investors, highlighting investment risks[8]. - The company has maintained compliance with regulatory decision-making procedures regarding external guarantees[9]. - The company has not engaged in non-operating fund occupation by controlling shareholders or related parties[9]. Research and Development - The company applied for 30 patents during the year, with 23 patents granted, including 3 invention patents and 18 utility model patents[60]. - The company focuses on the development of generic and innovative drugs, particularly in cardiovascular, digestive, and neurodegenerative disease areas[130]. - The company has included 40 products in the 2019 version of the National Medical Insurance Directory, with one product removed[126]. - The company aims to enhance its product structure by diversifying its generic drug offerings and improving existing products[130]. - The company plans to submit clinical applications for three innovative drugs within 1-2 years[128]. - The company's R&D investment for the reporting period was CNY 230.82 million, accounting for 6.18% of operating revenue, which is above the industry average[137]. - The cumulative R&D investment for key projects includes CNY 1,539.57 million for Ticagrelor and CNY 1,673.11 million for Dapagliflozin, both of which have completed registration submissions[140]. - The company has made significant progress in product development, with TRN-157 showing a cumulative R&D investment of CNY 1,002.00 million and currently in preclinical research[142]. Market and Industry Trends - The pharmaceutical industry saw a revenue growth of 9.4% in 2019, with profits increasing by 11.5%[41]. - The pharmaceutical manufacturing industry is undergoing structural adjustments and upgrades, driven by government policies and an aging population[96]. - The company is focusing on high-end specialty raw materials and process improvements to reduce costs in the raw material drug sector[96]. - The "4+7" centralized drug procurement policy has expanded to 25 provinces, indicating a significant shift in the pharmaceutical market dynamics[101]. - The introduction of consistency evaluation for chemical drug injections is expected to accelerate the upgrade of generic drug companies and enhance market competition[105]. - The company aims to strengthen its market share in niche products by leveraging its channel and brand advantages[107]. - The ongoing consistency evaluation for oral solid preparations is progressing, with a focus on risk assessment for new product projects[111]. Production and Sales - The company has a comprehensive product chain in the antibiotic field, covering over 500 specifications including raw materials and formulations[34]. - Revenue from amoxicillin capsules reached 176 million yuan, a year-on-year increase of 20.73%, while cefalexin capsules generated 105 million yuan, up 32.66%[46]. - Sales of penicillin sodium salt and sulbactam sodium increased by 47.37% and 45.3% respectively, while cefazolin sodium and cefazolin acid surged by 145.6% and 379.3%[46]. - The company reported a production volume of 99 million units for Penicillin Sodium, with sales reaching 35 million units[121]. - The production volume for Cefoperazone Sodium for injection was 9,162 million units, with sales of 7,979 million units[121]. - The company produced 196 tons of Cefoperazone Sodium, achieving sales of 90 tons[121]. Financial Management - The company received a standard unqualified audit report from its accounting firm[6]. - The company is committed to ensuring the accuracy and completeness of its financial reports[6]. - The company’s asset-liability ratio rose to 55.26%, an increase of 1.08 percentage points year-on-year[56]. - The company’s cash and cash equivalents decreased significantly, reflecting a strategic shift in financial management[89]. - The company’s investment in construction projects increased by 70.24% to $660,338,804.09, indicating ongoing expansion efforts[89]. Environmental and Regulatory Compliance - The company is committed to enhancing its environmental governance and ensuring compliance with new pollution discharge standards[113]. - The implementation of the new environmental standards for pharmaceutical emissions will require companies to enhance their pollution control measures[112]. - The company faces risks related to industry policy changes, environmental regulations, and the high costs and uncertainties associated with drug research and development[174][176].